Clinical Trials Logo

Herpangina clinical trials

View clinical trials related to Herpangina.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06263439 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Surveillance of HFMD in Pediatric Outpatients

PMB
Start date: June 20, 2023
Phase:
Study type: Observational

The aims of this prospective multicentric study is to determine the types of enteroviruses (EVs) responsible for hand, foot and mouth disease (HFMD) or herpangina in children seen within an ambulatory setting : - to detect an EV-A71 epidemic or another type associated with atypical forms of the disease at an early stage - to describe and compare the epidemiological, demographic, clinical and virological characteristics of these infections between the different types of EV.

NCT ID: NCT06063057 Recruiting - Clinical trials for Hand, Foot and Mouth Disease

Inactivated Bivalent Enterovirus Vaccine (Vero Cell) Phase I/II Clinical Trial

Start date: September 20, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

The Phase I clinical trial is divided into two parts. The first part uses an open-label design, while the second part uses a randomized, double-blind, and controlled design. The goal of this clinical trial is to evaluate the tolerability and safety of a bivalent (EV71/CA16, Enterovirus 71/Coxsackievirus A16) inactivated enterovirus vaccine (Vero cell) developed by Sinovac. The vaccine will be administered to healthy adults, children aged 6 to 12 years, and children aged 6 to 71 months. The Phase II clinical trial will also use a randomized, double-blind, and controlled design to evaluate the safety and immunogenicity of the same bivalent inactivated enterovirus vaccine (Vero cell) developed by Sinovac. This trial will involve healthy children aged 6 to 71 months.